Peptides
Daily subcutaneous
Targets visceral fat
The growth hormone releasing analogue with the strongest clinical evidence for reducing visceral abdominal fat specifically.
Prescription treatment. Prescribed only when clinically appropriate, after review by a licensed provider.
What to expect
Clinically studied for visceral fat reduction
Supports growth hormone release through the natural axis
May improve lipid markers
Targets the abdominal fat most linked to metabolic risk
How it works
Tesamorelin is a stabilised analogue of growth hormone releasing hormone. Its effect on visceral adipose tissue, the deep fat surrounding the organs, is the best documented of the secretagogues.
Individual results vary.
Dosing
Administered by daily subcutaneous injection, usually in defined cycles with provider review before renewal.
Safety information
Possible side effects
Not suitable for
Prescription treatment. Prescribed only when clinically appropriate, after review by a licensed provider. This is not a complete list of risks. Your provider will review your full medical history before prescribing.
Questions
Both act on the same axis, but tesamorelin has specific clinical trial evidence for visceral fat reduction, which is why it is chosen when that is the goal.
Related treatments
Ready when you are
A licensed provider reviews your intake and prescribes tesamorelin only when clinically appropriate. Individual results vary.
Start your online visitPrescription treatment. Prescribed only when clinically appropriate, after review by a licensed provider.
